Japan Approves the World's First Treatment Made With Reprogrammed Human Cells Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology. Human iPS cell colony established from fibroblasts. Its actual width is approximately 0.5 mm. On March 6, Japan's Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells .

Before that, it is crucial to develop benchmarks to evaluate L VLMs' effectiveness in various medical applications.

The examination of blood samples at a microscopic level plays a fundamental role in clinical diagnostics. For instance, an in-depth study of White Blood Cells (WBCs), a crucial component of our blood, is essential for diagnosing blood-related diseases such as leukemia and anemia. While multiple datasets containing WBC images have been proposed, they mostly focus on cell categorization, often lacking the necessary morphological details to explain such categorizations, despite the importance of explainable artificial intelligence (XAI) in medical domains. This paper seeks to address this limitation by introducing comprehensive annotations for WBC images. Through collaboration with pathologists, a thorough literature review, and manual inspection of microscopic images, we have identified 11 morphological attributes associated with the cell and its components (nucleus, cytoplasm, and granules). We then annotated ten thousand WBC images with these attributes, resulting in 113k labels (11 attributes x 10.3k images). Annotating at this level of detail and scale is unprecedented, offering unique value to AI in pathology. Moreover, we conduct experiments to predict these attributes from cell images, and also demonstrate specific applications that can benefit from our detailed annotations. Overall, our dataset paves the way for interpreting WBC recognition models, further advancing XAI in the fields of pathology and hematology.

We present a method called Manifold Interpolating Optimal-Transport Flow (MIOFlow) that learns stochastic, continuous population dynamics from static snapshot samples taken at sporadic timepoints. MIOFlow combines dynamic models, manifold learning, and optimal transport by training neural ordinary differential equations (Neural ODE) to interpolate between static population snapshots as penalized by optimal transport with manifold ground distance. Further, we ensure that the flow follows the geometry by operating in the latent space of an autoencoder that we call a geodesic autoencoder (GAE). In GAE the latent space distance between points is regularized to match a novel multiscale geodesic distance on the data manifold that we define. We show that this method is superior to normalizing flows, Schr\odinger bridges and other generative models that are designed to flow from noise to data in terms of interpolating between populations. Theoretically, we link these trajectories with dynamic optimal transport. We evaluate our method on simulated data with bifurcations and merges, as well as scRNA-seq data from embryoid body differentiation, and acute myeloid leukemia treatment.

Background. Subdural hematoma (SDH) is a common neurosurgical emergency, with increasing incidence in aging populations. Rapid and accurate identification is essential to guide timely intervention, yet existing automated tools focus primarily on detection and provide limited interpretability or spatial localization. There remains a need for transparent, high-performing systems that integrate multimodal clinical and imaging information to support real-time decision-making. Methods. We developed a multimodal deep-learning framework that integrates structured clinical variables, a 3D convolutional neural network trained on CT volumes, and a transformer-enhanced 2D segmentation model for SDH detection and localization. Using 25,315 head CT studies from Hartford HealthCare (2015--2024), of which 3,774 (14.9\%) contained clinician-confirmed SDH, tabular models were trained on demographics, comorbidities, medications, and laboratory results. Imaging models were trained to detect SDH and generate voxel-level probability maps. A greedy ensemble strategy combined complementary predictors. Findings. Clinical variables alone provided modest discriminatory power (AUC 0.75). Convolutional models trained on CT volumes and segmentation-derived maps achieved substantially higher accuracy (AUCs 0.922 and 0.926). The multimodal ensemble integrating all components achieved the best overall performance (AUC 0.9407; 95\% CI, 0.930--0.951) and produced anatomically meaningful localization maps consistent with known SDH patterns. Interpretation. This multimodal, interpretable framework provides rapid and accurate SDH detection and localization, achieving high detection performance and offering transparent, anatomically grounded outputs. Integration into radiology workflows could streamline triage, reduce time to intervention, and improve consistency in SDH management.

We present ClinicalTrialsHub, an interactive search-focused platform that consolidates all data from ClinicalTrials.gov and augments it by automatically extracting and structuring trial-relevant information from PubMed research articles. Our system effectively increases access to structured clinical trial data by 83.8% compared to relying on ClinicalTrials.gov alone, with potential to make access easier for patients, clinicians, researchers, and policymakers, advancing evidence-based medicine. ClinicalTrialsHub uses large language models such as GPT-5.1 and Gemini-3-Pro to enhance accessibility. The platform automatically parses full-text research articles to extract structured trial information, translates user queries into structured database searches, and provides an attributed question-answering system that generates evidence-grounded answers linked to specific source sentences. We demonstrate its utility through a user study involving clinicians, clinical researchers, and PhD students of pharmaceutical sciences and nursing, and a systematic automatic evaluation of its information extraction and question answering capabilities.

Modern science advances fastest when thought meets action. LabOS represents the first AI co-scientist that unites computational reasoning with physical experimentation through multimodal perception, self-evolving agents, and Extended-Reality(XR)-enabled human-AI collaboration. By connecting multi-model AI agents, smart glasses, and robots, LabOS allows AI to see what scientists see, understand experimental context, and assist in real-time execution. Across applications -- from cancer immunotherapy target discovery to stem-cell engineering and material science -- LabOS shows that AI can move beyond computational design to participation, turning the laboratory into an intelligent, collaborative environment where human and machine discovery evolve together.